SABCS 2023

YiR in EBC #1: New data in HER2+ and Immunotherapy in HR+ and TNBC

YiR in EBC #2: De-escalating therapy in locoregional recurrence, adjuant therapy with CDK4/6i and new insights in pregnancy/fertility preservation after EBC

YiR in ABC #1: Exciting new data for first line mTNBC, progress in HER2+ therapy and new data on triple-positive disease

YiR in ABC #2: New data on treatment in metastatic HR+ breast cancer - CDK4/6i and beyond

YiR in ABC #3: Exciting new data on ADCs in HR+ breast cancer

Final iDSF analysis in NATALEE

KEYNOTE-756 - Subgroup analysis

An enrichment of therapy options in the endocrine treatment of HR+ breast cancer

Hope with CPI for luminal breast cancer

SABCS23 highlights in early breast cancer

CheckMate7FL - Biomarker

ADAPTcycle - endocrine response

cTDNA analyses in monarchE

Prediction of pCR in KEYNOTE-756

Change in the standard of follow-up care?

KATHERINE: OS improvement in HER2+ eBC

T-DM1 in post-neoadjuvant therapy now also with OS-benefit

Immunotherapy for early TNBC must be neoadjuvant

Pregnancy despite endocrine therapy in HR+ breast cancer

Pregnancy after BC is safe - also in germline BRCA+ pts

Importance of the onco-fertility discussion

Anthtracyclines in EBC: to give or not to give?

Análisis de cTDNA en monarchE

SABCS23 evidenzia il cancro al mammario in fase precoce

Importância da discussão sobre onco-fertilidade

Gravidanza dopo la diagnosi di carcinoma mammario è sicura anche nelle pazienti gBRCA+

KATHERINE : amélioration de la survie globale dans le cancer du sein précoce HER2+

Dato-Dxd achieves PFS

T-DXd + endocrine therapy interesting for HR+ HER2low mBC

Is OS important?

Fulvestrant + futibatinib interesting for FGFR1 amplifications

OS benefit with fulvestrant/letrozole + palbocilib is similar to othter CDK4/6i in first line

Long follow-up of CDK4/6i

Capiversatib + Palbociclib + Fulvestrant in HR+ HER2- mBC

MONARCH 3 shows clinically relevant OS-benefit without statistical significance

Letrozole + palbo as effective as fulvestrant + palbo

SABCS23 highlights in metastatic breast cancer

Promising data for the PIK3CA-inhibitor inavolisib

Does abemciclib lead to improved OS survival in the 1st line setting?

PIK3CA-inhibitor: positive results in Phase III

Final OS analysis in MONARCH 3

Tucatinib + T-DM1: Possible role in the contemporary landscape?

Tucatinib + T-DM1 interesting for specific patients

New potential backbone for tucatinib in mHER2+ BC

Avelumab appears to be effective in HER2+ mBC

Effective, chemo-free combination for triple-positive MBC

Efficacy of tucatinib confirmed, but unclear for which patients still relevant

KEYLYNK-009: Pembrolizumab + olaparib a well-tolerated combination

Positive sentinel lymph node after mastectomy

Axillary surgery de-escalation

Metastatic patients can and must exercise

Rethinking management of the axilla

Axillary radiotherapy can be omitted in T3N1 BC pts

Isolated tumor cells in the sentinel lymph node - does it have to be the axilla dissection?

Physical acitivity improves QoL in advanced BC

Poster insights: PO4-01-10 ADAPTcycle

Low-dose olanzapine more favorable in the prophylaxis of CINV

L'attività fisica migliora la qualità di vita nel cancro al seno avanzato

La supervivencia obtenida con palbociclib y letrozol/fulvestrant es similar a la de otros CDK4/6i en primera línea

Tucatinib + T-DM1: Possibile un ruolo nello scenario attuale?

Tukatynib skuteczny, ale czy umiemy określić jego miejsce?

Desescalada de cirugía axilar

Dato-Dxd consigue PFS

Capiversatib + Palbociclib + Fulvestrant dans le cancer du sein HR+ HER2-

Duże zmiany w leczeniu pachy

La radioterapia ascellare può essere omessa nelle pazienti con carcinoma mammario T3N1

Inhibiteur de PIK3CA: résultats positifs en phase III

Capiversatib + Palbociclib + Fulvestrant nel carcinoma mammario HR+ HER2-

SABCS23 evidenzia nel cancro al mammario metastatico

Immunotherapy and combination therapies for HR+/HER2- and TNBC

New and good therapy options for HER2+ patients

No significant OS - but what is the impact on clincial practice?!

Pregnancy is safe after endocrine therapy

De-escalation of radiotherapy after neoadjuvant therapy

DE-escalation of the axillary interverntion after neoadjuvant therapy

Good balance between benefits and side effect - but not guideline changing, yet?!

OS and final iDFS data - confirming data but risk and benefits must be balanced

Final iDFS data - is everything clear yet?

PI3K inihbitor Inavolisib shows improved PFS - one step closer to a new era?!